ClinicalTrials.gg
CompletedNCT01210560Updated Jun 14, 2018Results posted

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

A Phase 2 interventional study of Tolvaptan MR and Tolvaptan MR in Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-06-14.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
13th of 18
25 · median 91
Started
2010
with 3 others
Phase 2
7 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 13th largest by enrollment, is one of 4 that started in 2010, is one of 7 in phase 2, and was the 5th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

To establish pharmacokinetics (PK), pharmacodynamics (PD), and adverse event (AE) profile of tolvaptan administered as the modified-release (MR) formulation in ADPKD subjects. The goals of this trial are two-fold:

  1. To directly compare the immediate release (IR) and MR formulations
  2. To determine the dose range and dose regimen for MR (dose finding)
Read the detailed description

Group 1 will have 12 subjects enrolled in a 3-period, randomized, crossover to compare multiple doses of a 90-30 mg split-dose of the tolvaptan IR formulation, a 120 mg once daily (QD) dose of the tolvaptan MR formulation, and, in an incomplete block randomization, multiple doses of either 20 mg QD, 60 mg QD, or 20 mg twice daily (BID) tolvaptan MR formulation. All dose regimens will be administered for 7 days. Placebo doses will be administered in order to mask QD vs BID treatments.

Group 2 will have 12 subjects enrolled in a 3-period, randomized, crossover to compare multiple oral doses of the tolvaptan MR formulation administered for 7 days as 20 mg QD, 60 mg QD, and 20 mg BID. Placebo capsules will be administered in order to mask QD vs BID treatments.

Subjects will have in-clinic assessments on 12 days to obtain 24-hour PK and PD data. Subjects will visit the clinic from the afternoon of Day -1 through the morning of Day 1. They will return at the end of each dosing period for a similar inpatient period (ie, from the afternoon of Day 6 through the morning of Day 8, from the afternoon of Day 13 through the morning of Day 15, from the afternoon of Day 20 through the morning of Day 22). Except for the first dose of each period and the doses taken in the clinic on the last day of each regimen and the afternoon of Days 6, 13 and 20, all other doses will be taken by the subject as an outpatient.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease

Keywords

  • Kidney Disease
  • Polycystic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects (male or female) who are surgically sterile (ie, have undergone hysterectomy) or using or agree to remain abstinent
  • Subjects between the ages of 18 and 50, inclusive
  • Subjects with a between 19 to 35 kg/m2 (inclusive)
  • Subjects with a diagnosis of ADPKD by modified Ravine criteria
  • Subjects must be in good health as determined by medical history, physical examination, , serum/urine biochemistry, hematology, and serology tests
  • Subjects with the ability to provide written, prior to initiation of any trial-related procedures, and ability, in the opinion of the principle investigator, to comply with all requirements of the trial
  • Subjects who expect to be able to complete all dosing periods and assessments within 42 (+2) days after dosing on Day 1

Exclusion criteria

Exclusion Criteria:

  • Subjects using diuretics within 14 days prior to check in on Day -1
  • Subjects with incontinence, overactive bladder, or urinary retention (eg, benign prostatic hyperplasia)
  • Subjects (male or female) with nocturia/urgency (outside of the 2 to 4 times awakening per night expected for ADPKD patients) at screening
  • Subjects with liver disease, liver function abnormalities or serology other than that expected for ADPKD with cystic liver disease at baseline
  • Subjects with abnormality in past medical history, or at the Screening physical examination, that in the investigator's or sponsor's opinion may place the volunteer at risk or interfere with outcome variables including absorption, distribution, metabolism, and excretion of drug. This includes, but is not limited to, history of or concurrent cardiac, hepatic, renal, neurologic, endocrine, gastrointestinal, respiratory, hematologic, and immunologic disease
  • Subjects with a history of drug and/or alcohol abuse within 2 years prior to screening
  • Subjects who have a history of or test positive at screening for surface antigen (HBsAg), antibodies (anti-HCV), and/or (HIV)
  • Subjects who have clinically significant allergic reactions to tolvaptan or chemically related structures such as benzazepines (eg, benzazepril, conivaptan, fenoldopam mesylate or mirtazapine)
  • Subjects who have taken an drug within 30 days preceding trial entry
  • Subjects with any history of significant bleeding or hemorrhagic tendencies
  • Subjects with a history of difficulty in donating blood
  • Subjects who have donated blood or plasma within 30 days prior to dosing
  • Subjects who have consumed alcohol and/or food or beverages containing methylxanthines, grapefruit, grapefruit juice, Seville oranges, or Seville orange juice within 72 hours prior to Day 1 dosing
  • Subjects taking inhibitors, with the exception of amiodarone, taken within 30 days of dosing (eg, amprenavir, atorvastatin, aprepitant, chloramphenicol [not eye drops], cimetidine, clarithromycin, clotrimazole [if used orally], danazol, delavirdine, diltiazem, erythromycin, fluconazole, fluvoxamine, indinavir, isoniazid, itraconazole, josamycin, ketoconazole, nelfinavir, nefazadone, quinupristin/dalfopristin, ritonavir, saquinavir, troleandomycin, verapamil)
  • Subjects taking CYP3A4 inducers taken within 7 days of dosing (eg, rifampin, St. Johns Wort)
  • Subjects with a history of serious mental disorders
  • Subjects with previous exposure to tolvaptan
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    20 mg MR

    Drug: Tolvaptan MR

  • Experimental
    40 mg MR

    Drug: Tolvaptan MR

  • Experimental
    60 mg MR

    Drug: Tolvaptan MR

  • Experimental
    120 mg MR

    Drug: Tolvaptan MR

  • Experimental
    120 mg IR

    Drug: Tolvaptan IR

Interventions

  • 20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days

    Also known as: OPC-41061

  • 20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days

    Also known as: OPC-41061

  • 60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days

    Also known as: OPC-41061

  • 90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days

    Also known as: OPC-41061

  • 120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days

    Also known as: OPC-41061

06

What researchers measure

Primary outcomes

  1. Maximum (Peak) Plasma Concentration of the Drug [Cmax] and Minimum (Trough) Plasma Concentration of the Drug [Cmin] After Tolvaptan Treatment on Day 7.

    Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Maximum and minimum plasma concentration of the drug was calculated.

    Time frame: Day 7

  2. Time to Maximum (Peak) Plasma Concentration (Tmax) After Tolvaptan Treatment on Day 7.

    Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Time to maximum plasma concentration was calculated.

    Time frame: Day 7

  3. Area Under the Concentration-time Curve During the Dosing Interval at Steady State and Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUCT & AUC0-24h) After Tolvaptan Treatment on Day 7.

    Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Hence, both AUCT and AUC0-24h values were calculated.

    Time frame: Day 7

Secondary outcomes

  1. Number of Participants With Urine Osmolality < 300 mOsm/kg at 23.5 Hours Postdose.

    For determination of duration of urine osmolality \<300 mOsm/kg, the value was the end time of the last collection interval in which urine osmolality was \<300 mOsm/kg. Day 8 in the table below was defined as Day 8 of Period 1, Day 15 of Period 2, and Day 22 of period 3.

    Time frame: 23.5 hours post-dose

  2. Change From Baseline in Urine Osmolality Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24h) at Day 7.

    The AUC0-24h for urine osmolality was determined by multiplying the concentration by the collection interval duration for each collection interval and summing all the intervals in the 24-hour period. If the urine volume for an interval is zero, the duration of that interval will be added to the next collection interval. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.

    Time frame: Day 7

  3. Change From Baseline in Urine Osmolality at Day 7.

    To determine the tolerability and nighttime urinary suppression of osmolality. The urine osmolality was summarized by collection interval (0 to 4, 4 to 8, 8 to 12, 12 to 16, and 16 to 24 hours)

    Time frame: 0-4, 4-8, 8-12, 12-16, 16-24 Hours at Day 7

  4. Change From Baseline in Urine Volume at 24 Hours at Day 7.

    Urine volume was collected by 0 to 24-hour interval at Day 7. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.

    Time frame: Day 7

  5. Change From Baseline in Urine Volume by Interval at Day 7.

    Urine volume collected was by interval (0-4, 4-8, 8-12, 12-16, 16-24 hours). Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.

    Time frame: 0-4, 4-8, 8-12, 12-16, 16-24 Hours at Day 7

  6. Duration of Urine Osmolality Less Than 300 mOsm/kg at Baseline and Day 7.

    Duration of urine osmolality remains below 300 mOsm/kg was the sum of the durations (nominal times) of all intervals where the urine concentration was \< 300 mOsm/kg. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2, and Day 21 of Period 3.

    Time frame: Baseline and Day 7

  7. Change From Baseline in Number of Urine Voids During Awake Periods.

    Average number of daily urine voids during awake periods for each dose group. Day 1 was defined as Day1 of Period 1, Day 8 of Period 2 adn Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 and Day 6.

    Time frame: Days 1, 2, 3, 4, 5, 6 and 7

  8. Change From Baseline in Number of Urine Voids During Sleep Periods.

    Average number of daily urine voids during sleep periods for each dose group. Day 1 was defined as Day 1 of Period 1, Day 8 of Period 2, Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 to 6.

    Time frame: Days 1, 2, 3, 4, 5, 6 and 7

  9. Change From Baseline in Symptom Burden by Autosomal Dominant Polycystic Kidney Disease (ADPKD) Nocturia Quality of Life Questionnaire at Day 6.

    In ADPKD Nocturia Quality of Life Questionnaire, questions 1 to 11 (with possible scores ranging from 0 to 4 and higher scores indicating better quality of life) were pooled to provide a total score (maximum of 44 points). Response scores of Question 12 (with possible scores ranging from 1 to 10, with higher scores indicating more interference (worse quality of life) with everyday life due to urination at night) were pooled separately. Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

    Time frame: Day 6

  10. Number of Participants Experiencing Urinary Urgency Based on Urinary Urgency Questionnaire (Question 1) at Baseline and Day 6.

    For the ADPKD Urinary Urgency Questionnaire, Question 1 (currently experiencing urgency?) was assigned 'Yes' or 'No' to measure current urine urgency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

    Time frame: Baseline and Day 6

  11. Change From Baseline in Urinary Urgency Questionnaire (Questions 2 to 5 and Questions 7 to 14) at Day 6.

    Question 2 to Question 6 were assigned scores of 0 to 4 with higher scores indicating worse cases in experience of urinary urgency. Scores for Question 2 to Question 5 were pooled, with a maximum possible score of 16. Question 6 was excluded from the analysis since it was only asked at screening. Question 7 to Question 14 were also assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary urgency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

    Time frame: Day 6

  12. Number of Participants Experiencing Urinary Frequency Based on Urinary Frequency Questionnaire (Question 1) at Baseline and Day 6.

    The ADPKD Urinary Frequency Questionnaire: Question 1 (currently experiencing frequency) was assigned 'Yes' or 'No' to measure current urine frequency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

    Time frame: Baseline and Day 6

  13. Change From Baseline in Urinary Frequency Questionnaire (Question 2 and Questions 3 to 10) at Day 6.

    Question 2 asked, "During the last 5 days, how much has urinary frequency bothered you?" In order to score the response, the written answers were assigned values from 0 to 4 as follows: 0) Not at all, 1) Somewhat, 2) Moderately, 3) Quite a bit, and 4) Constantly. Question 3 to Question 10 were assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary frequency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

    Time frame: Day 6

  14. Ranking of Treatment Tolerability.

    Ranking of treatment tolerability was evaluated based on a questionnaire. At Day 22, participants were asked the following questions and their responses recorded on the eCRF: "Which treatment period did you find most tolerable?" and "Which treatment period did you find the least tolerable?".

    Time frame: Day 22/Early Termination

07

Results

Posted Jun 14, 2018

Participant flow

Study was conducted at 6 centers in the United States. 25 participants were randomized (12+13) to Group 1 \& 2 with 5 \& 3 treatment sequences, respectively; received tolvaptan Modified-release \[MR\] capsules \& Immediate-release \[IR\] tablets in Group 1 \& MR in Group 2 over 3 therapy periods (each 7 days) in parallel-group, crossover design

Intervention 1 (7 Days)
Participant flow — Intervention 1 (7 Days)
MilestoneGroup 1: DAEGroup 1: DBEGroup 1: DCEGroup 1: EADGroup 1: EBDGroup 1: ECDGroup 2: FGHGroup 2: HFGGroup 2: GHF
Started222222445
Completed222222445
Not completed000000000
Intervention 2 (7 Days)
Participant flow — Intervention 2 (7 Days)
MilestoneGroup 1: DAEGroup 1: DBEGroup 1: DCEGroup 1: EADGroup 1: EBDGroup 1: ECDGroup 2: FGHGroup 2: HFGGroup 2: GHF
Started222222445
Completed222222445
Not completed000000000
Intervention 3 (7 Days)
Participant flow — Intervention 3 (7 Days)
MilestoneGroup 1: DAEGroup 1: DBEGroup 1: DCEGroup 1: EADGroup 1: EBDGroup 1: ECDGroup 2: FGHGroup 2: HFGGroup 2: GHF
Started222222445
Completed222222445
Not completed000000000

Outcome measures

PrimaryMaximum (Peak) Plasma Concentration of the Drug [Cmax] and Minimum (Trough) Plasma Concentration of the Drug [Cmin] After Tolvaptan Treatment on Day 7.

Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Maximum and minimum plasma concentration of the drug was calculated.

Time frame:
Day 7
Reported as:
Mean · ng/mL
Maximum (Peak) Plasma Concentration of the Drug [Cmax] and Minimum (Trough) Plasma Concentration of the Drug [Cmin] After Tolvaptan Treatment on Day 7.
ng/mLMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Cmax140 ± 68.4175 ± 60.1350 ± 156669 ± 370716 ± 344
Cmin14.7 ± 9.9550.8 ± 24.051.1 ± 32.3139 ± 75.557.5 ± 41.8
PrimaryTime to Maximum (Peak) Plasma Concentration (Tmax) After Tolvaptan Treatment on Day 7.

Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Time to maximum plasma concentration was calculated.

Time frame:
Day 7
Reported as:
Median · Hours
Time to Maximum (Peak) Plasma Concentration (Tmax) After Tolvaptan Treatment on Day 7.
HoursMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Time to Maximum (Peak) Plasma Concentration (Tmax) After Tolvaptan Treatment on Day 7.6.00 (3.97 to 10.00)6.00 (3.97 to 16.00)6.00 (3.98 to 9.00)5.98 (3.97 to 6.00)2.00 (1.00 to 9.00)
PrimaryArea Under the Concentration-time Curve During the Dosing Interval at Steady State and Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUCT & AUC0-24h) After Tolvaptan Treatment on Day 7.

Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Hence, both AUCT and AUC0-24h values were calculated.

Time frame:
Day 7
Reported as:
Mean · ng·h/mL
Area Under the Concentration-time Curve During the Dosing Interval at Steady State and Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUCT & AUC0-24h) After Tolvaptan Treatment on Day 7.
ng·h/mLMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Area Under the Concentration-time Curve During the Dosing Interval at Steady State and Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUCT & AUC0-24h) After Tolvaptan Treatment on Day 7.1260 ± 6542310 ± 7043600 ± 16707740 ± 36506570 ± 3230
SecondaryNumber of Participants With Urine Osmolality < 300 mOsm/kg at 23.5 Hours Postdose.

For determination of duration of urine osmolality \<300 mOsm/kg, the value was the end time of the last collection interval in which urine osmolality was \<300 mOsm/kg. Day 8 in the table below was defined as Day 8 of Period 1, Day 15 of Period 2, and Day 22 of period 3.

Time frame:
23.5 hours post-dose
Reported as:
Count of participants · Participants
Number of Participants With Urine Osmolality < 300 mOsm/kg at 23.5 Hours Postdose.
ParticipantsMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Baseline11100
Day 851191111
SecondaryChange From Baseline in Urine Osmolality Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24h) at Day 7.

The AUC0-24h for urine osmolality was determined by multiplying the concentration by the collection interval duration for each collection interval and summing all the intervals in the 24-hour period. If the urine volume for an interval is zero, the duration of that interval will be added to the next collection interval. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.

Time frame:
Day 7
Reported as:
Mean · mOsm/kg*Hour
Change From Baseline in Urine Osmolality Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24h) at Day 7.
mOsm/kg*HourMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Change From Baseline in Urine Osmolality Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24h) at Day 7.-2546 ± 1743-3438 ± 2277-4209 ± 2569-4325 ± 2237-4620 ± 2419
SecondaryChange From Baseline in Urine Osmolality at Day 7.

To determine the tolerability and nighttime urinary suppression of osmolality. The urine osmolality was summarized by collection interval (0 to 4, 4 to 8, 8 to 12, 12 to 16, and 16 to 24 hours)

Time frame:
0-4, 4-8, 8-12, 12-16, 16-24 Hours at Day 7
Reported as:
Mean · mOsm/kg
Change From Baseline in Urine Osmolality at Day 7.
mOsm/kgMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
0-4 Hour2.6 ± 132.1-0.7 ± 111.9-88.9 ± 130.9-59.5 ± 169.2-123.3 ± 139.5
4-8 Hour-140.9 ± 127.1-128.3 ± 127.2-188.2 ± 140.5-186.1 ± 161.1-191.8 ± 155.1
8-12 Hour-123.1 ± 115.9-172.1 ± 129.8-201.8 ± 158.8-167.1 ± 148.7-166.9 ± 131.7
12-16 Hour-128.3 ± 142.9-193.6 ± 152.5-195.8 ± 151.6-176.3 ± 121.8-178.3 ± 128.9
16-24 Hour-123.4 ± 102.6-182.4 ± 145.6-188.8 ± 160.0-246.1 ± 108.9-239.8 ± 117.8
SecondaryChange From Baseline in Urine Volume at 24 Hours at Day 7.

Urine volume was collected by 0 to 24-hour interval at Day 7. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.

Time frame:
Day 7
Reported as:
Mean · mL
Change From Baseline in Urine Volume at 24 Hours at Day 7.
mLMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Change From Baseline in Urine Volume at 24 Hours at Day 7.1111 ± 9192066 ± 12372396 ± 10223722 ± 17763820 ± 1759
SecondaryChange From Baseline in Urine Volume by Interval at Day 7.

Urine volume collected was by interval (0-4, 4-8, 8-12, 12-16, 16-24 hours). Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.

Time frame:
0-4, 4-8, 8-12, 12-16, 16-24 Hours at Day 7
Reported as:
Mean · mL
Change From Baseline in Urine Volume by Interval at Day 7.
mLMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
0-4 Hour-87 ± 348-118 ± 39156 ± 34587 ± 449241 ± 412
4-8 Hour326 ± 531423 ± 439636 ± 382785 ± 605825 ± 472
8-12 Hour301 ± 317529 ± 349689 ± 603887 ± 558801 ± 494
12-16 Hour314 ± 328635 ± 473667 ± 337926 ± 459910 ± 738
16-24 Hour257 ± 407598 ± 482286 ± 4211038 ± 6421044 ± 421
SecondaryDuration of Urine Osmolality Less Than 300 mOsm/kg at Baseline and Day 7.

Duration of urine osmolality remains below 300 mOsm/kg was the sum of the durations (nominal times) of all intervals where the urine concentration was \< 300 mOsm/kg. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2, and Day 21 of Period 3.

Time frame:
Baseline and Day 7
Reported as:
Median · Hours
Duration of Urine Osmolality Less Than 300 mOsm/kg at Baseline and Day 7.
HoursMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Baseline8.0 (0 to 24.0)8.0 (0 to 24.0)8.0 (0 to 24.0)14.0 (0 to 24.0)14.0 (0 to 24.0)
Day 716.0 (4.0 to 24.0)24.0 (4.0 to 24.0)24.0 (8.0 to 24.0)24.0 (20.0 to 24.0)24.0 (24.0 to 24.0)
SecondaryChange From Baseline in Number of Urine Voids During Awake Periods.

Average number of daily urine voids during awake periods for each dose group. Day 1 was defined as Day1 of Period 1, Day 8 of Period 2 adn Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 and Day 6.

Time frame:
Days 1, 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Number of urine voids
Change From Baseline in Number of Urine Voids During Awake Periods.
Number of urine voidsMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Day 11.7 ± 4.11.5 ± 3.13.5 ± 4.35.6 ± 5.64.8 ± 4.1
Day 2-0.4 ± 2.91.2 ± 4.01.8 ± 4.14.8 ± 7.83.8 ± 4.2
Day 3-0.8 ± 2.40.9 ± 2.42.4 ± 3.93.1 ± 4.63.3 ± 5.2
Day 4-1.4 ± 2.31.5 ± 3.80.4 ± 5.02.8 ± 5.03.7 ± 5.9
Day 5-0.5 ± 2.90.6 ± 3.5-0.4 ± 4.23.3 ± 5.64.0 ± 4.9
Day 60.0 ± 3.32.9 ± 4.15.8 ± 10.62.3 ± 6.84.8 ± 5.2
Day 72.0 ± 3.03.5 ± 2.43.5 ± 3.82.8 ± 6.44.3 ± 4.5
SecondaryChange From Baseline in Number of Urine Voids During Sleep Periods.

Average number of daily urine voids during sleep periods for each dose group. Day 1 was defined as Day 1 of Period 1, Day 8 of Period 2, Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 to 6.

Time frame:
Days 1, 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Number of urine voids
Change From Baseline in Number of Urine Voids During Sleep Periods.
Number of urine voidsMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Day 10.6 ± 1.61.1 ± 2.00.4 ± 2.22.5 ± 1.71.5 ± 1.6
Day 2-0.2 ± 1.70.8 ± 1.60.8 ± 1.91.8 ± 1.41.7 ± 1.2
Day 30.1 ± 1.01.4 ± 2.40.8 ± 1.71.9 ± 1.51.9 ± 1.7
Day 40.6 ± 2.30.7 ± 1.60.5 ± 1.71.7 ± 1.31.8 ± 1.9
Day 50.3 ± 1.30.9 ± 2.00.2 ± 1.41.0 ± 2.00.9 ± 1.7
Day 61.2 ± 3.31.3 ± 2.00.4 ± 1.61.1 ± 2.11.7 ± 1.7
Day 70.1 ± 1.31.0 ± 1.70.9 ± 1.81.8 ± 2.42.1 ± 1.9
SecondaryChange From Baseline in Symptom Burden by Autosomal Dominant Polycystic Kidney Disease (ADPKD) Nocturia Quality of Life Questionnaire at Day 6.

In ADPKD Nocturia Quality of Life Questionnaire, questions 1 to 11 (with possible scores ranging from 0 to 4 and higher scores indicating better quality of life) were pooled to provide a total score (maximum of 44 points). Response scores of Question 12 (with possible scores ranging from 1 to 10, with higher scores indicating more interference (worse quality of life) with everyday life due to urination at night) were pooled separately. Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

Time frame:
Day 6
Reported as:
Mean · Units on a scale
Change From Baseline in Symptom Burden by Autosomal Dominant Polycystic Kidney Disease (ADPKD) Nocturia Quality of Life Questionnaire at Day 6.
Units on a scaleMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Nocturia Quality of life Question (Q) 1 To Q 11-1.5 ± 4.3-6.9 ± 9.9-5.1 ± 7.6-15.0 ± 13.3-13.1 ± 12.3
Nocturia Quality of life Q 120.6 ± 1.31.9 ± 2.71.4 ± 2.54.2 ± 3.63.7 ± 3.5
SecondaryNumber of Participants Experiencing Urinary Urgency Based on Urinary Urgency Questionnaire (Question 1) at Baseline and Day 6.

For the ADPKD Urinary Urgency Questionnaire, Question 1 (currently experiencing urgency?) was assigned 'Yes' or 'No' to measure current urine urgency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

Time frame:
Baseline and Day 6
Reported as:
Number · Participants
Number of Participants Experiencing Urinary Urgency Based on Urinary Urgency Questionnaire (Question 1) at Baseline and Day 6.
ParticipantsMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Baseline53322
Day 6813121011
SecondaryChange From Baseline in Urinary Urgency Questionnaire (Questions 2 to 5 and Questions 7 to 14) at Day 6.

Question 2 to Question 6 were assigned scores of 0 to 4 with higher scores indicating worse cases in experience of urinary urgency. Scores for Question 2 to Question 5 were pooled, with a maximum possible score of 16. Question 6 was excluded from the analysis since it was only asked at screening. Question 7 to Question 14 were also assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary urgency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

Time frame:
Day 6
Reported as:
Mean · Units on a scale
Change From Baseline in Urinary Urgency Questionnaire (Questions 2 to 5 and Questions 7 to 14) at Day 6.
Units on a scaleMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Urinary urgency questionnaire-Question (Q) 2 to Q51.4 ± 2.13.2 ± 2.43.2 ± 3.14.6 ± 3.94.7 ± 3.0
Urinary urgency questionnaire-Q 7 to Q 140.9 ± 1.24.2 ± 5.53.5 ± 5.010.9 ± 10.98.8 ± 9.8
SecondaryNumber of Participants Experiencing Urinary Frequency Based on Urinary Frequency Questionnaire (Question 1) at Baseline and Day 6.

The ADPKD Urinary Frequency Questionnaire: Question 1 (currently experiencing frequency) was assigned 'Yes' or 'No' to measure current urine frequency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

Time frame:
Baseline and Day 6
Reported as:
Number · Participants
Number of Participants Experiencing Urinary Frequency Based on Urinary Frequency Questionnaire (Question 1) at Baseline and Day 6.
ParticipantsMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Baseline54444
Day 61015161212
SecondaryChange From Baseline in Urinary Frequency Questionnaire (Question 2 and Questions 3 to 10) at Day 6.

Question 2 asked, "During the last 5 days, how much has urinary frequency bothered you?" In order to score the response, the written answers were assigned values from 0 to 4 as follows: 0) Not at all, 1) Somewhat, 2) Moderately, 3) Quite a bit, and 4) Constantly. Question 3 to Question 10 were assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary frequency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.

Time frame:
Day 6
Reported as:
Mean · Units on a scale
Change From Baseline in Urinary Frequency Questionnaire (Question 2 and Questions 3 to 10) at Day 6.
Units on a scaleMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Urinary frequency questionnaire-Question (Q) 20.4 ± 0.61.1 ± 1.10.9 ± 0.91.7 ± 1.41.5 ± 1.1
Urinary frequency questionnaire-Q 3 to Q 101.4 ± 2.14.6 ± 6.94.1 ± 5.712.2 ± 11.09.1 ± 10.5
SecondaryRanking of Treatment Tolerability.

Ranking of treatment tolerability was evaluated based on a questionnaire. At Day 22, participants were asked the following questions and their responses recorded on the eCRF: "Which treatment period did you find most tolerable?" and "Which treatment period did you find the least tolerable?".

Time frame:
Day 22/Early Termination
Reported as:
Number · Participants
Ranking of Treatment Tolerability.
ParticipantsMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
Most tolerable Group 132311
Most tolerable Group 210—3——
Least tolerable Group 10——46
Least tolerable Group 2076——

Adverse events

Collected over Screening to seven days (+ 1 day) after the last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MR 20 mg—0/17 (0%)5/17 (29.4%)
MR 20+20 mg—0/17 (0%)10/17 (58.8%)
MR 60 mg—0/17 (0%)6/17 (35.3%)
MR 120 mg—0/12 (0%)8/12 (66.7%)
IR 90+30 mg—0/12 (0%)7/12 (58.3%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventMR 20 mgMR 20+20 mgMR 60 mgMR 120 mgIR 90+30 mg
PolyuriaRenal and urinary disorders2/175/171/174/125/12
PolydipsiaMetabolism and nutrition disorders1/172/170/172/123/12
NocturiaRenal and urinary disorders1/172/171/171/123/12
ThirstGeneral disorders1/173/172/172/121/12
NauseaGastrointestinal disorders0/170/171/172/121/12
PollakiuriaRenal and urinary disorders2/172/171/172/120/12
HeadacheNervous system disorders0/172/171/171/120/12
Micturition urgencyRenal and urinary disorders2/172/170/171/120/12
Abdominal distensionGastrointestinal disorders0/170/170/170/121/12
DiarrhoeaGastrointestinal disorders0/170/170/171/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group 1Group 2Total
Mean39.4 ± 4.336.8 ± 9.038.0 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Total
Female7411
Male5914
08

Study locations

6 sites
  • Tufts-New England Medical Center
    Boston, Massachusetts 02111, United States
  • Davita Clinical Research
    Minneapolis, Minnesota 55404, United States
  • Mayo Medical Center
    Rochester, Minnesota 55905, United States
  • University Hospitals of Cleveland/Case
    Cleveland, Ohio 44106, United States
  • Northwest Renal Clinic Inc.
    Portland, Oregon 97210, United States
  • University of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2018, 7 years after primary completion. A results delay was requested in Feb 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2010
First posted
Sep 28, 2010
Start
Oct 2010
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results delay requested
Feb 20, 2012
Results first posted
Jun 14, 2018
Last update
Jun 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01210560
Responsible party
Sponsor
First posted
Sep 28, 2010
Start date
Oct 2010
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jun 14, 2018
Last update
Jun 14, 2018

Study contacts

Frank Czerwiec, M.D., Ph.D.
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion